Denis DELVAL is appointed President of the Ethypharm Group

10 Oct 2022
www.prnewswire.com
SAINT-CLOUD, France, Oct. 10, 2022 /PRNewswire/ --
The Supervisory Board appointed Denis DELVAL as CEO of the Ethypharm Group.
Denis DELVAL, Doctor of Pharmacy, graduate of ESSEC and INSEAD, has an impressive range of experience in the pharmaceutical industry where he has spent his entire career in France and internationally in large and medium-sized groups (Bayer, Fournier Pharma, ALK, LFB).
Continue Reading
Denis DELVAL is appointed President of the Ethypharm Group
Preview
Source: PRNewswire
Le Conseil de Surveillance a nommé Denis DELVAL comme PDG du Groupe Ethypharm.
He has held positions of increasing importance in marketing, sales, strategy and general management, notably at ALK, the leading Danish company in allergy desensitisation treatments, where he was responsible for the French subsidiary and then Senior Vice-President Europe.
In 2017, he was appointed President of LFB, a biopharmaceutical group that develops, manufactures and markets medicinal products derived from living matter. He has profoundly changed the company and has committed it at all levels to a transformation process based on shared values.
"I am proud to join Ethypharm, a European company with French roots, specialising in Central Nervous System (CNS) diseases and hospital injectables. I look forward to mobilising energies and continuing the development of the Group", Denis DELVAL announced.
About the Ethypharm Group
Ethypharm is a European pharmaceutical company specialising in two areas: the Central Nervous System and Hospital Injectable Medicines. Ethypharm markets its medicines directly in Europe and China, and works with partners in North America and the Middle East where its medicines are in high demand. The Group employs more than 1,750 people, mainly based in Europe and China.
Ethypharm works closely with the authorities and health professionals to ensure the appropriate use of and access to its medicines for as many people as possible.
For more information on Ethypharm, please visit www.ethypharm.com and follow us on LinkedIn.
Photo - https://mma.prnewswire.com/media/1917066/Denis_Delval_Ethypharm.jpg
Logo - https://mma.prnewswire.com/media/1917067/Ethypharm_Logo.jpg
Press contact
[email protected]
SOURCE Ethypharm Digital Therapy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.